Skip to main content
All lobbying filings

STANTON PARK GROUP

Lobbying for VERTEX PHARMACEUTICALS INCORPORATED · Global biotechnology company

 Filing 4th Quarter - Report
4th Quarter (Oct 1 - Dec 31) 2025 · Massachusetts · House · Senate · $50,000.00 income · posted Jan 20, 2026

Official filing document

 Bills named in this filing 2
 Lobbying activity 1
Health Issues

Patient access to rare and orphan disease therapeutics; FDA regulatory pathways for pharmaceuticals; Awareness of Cystic Fibrosis and Sickle Cell Disease; Education about non-opioid pain therapies and Medicare beneficiary access to non-opioid medicines; HR 7142 and S. 3832

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem